Liaoning Chengda Biotechnology Co.,Ltd. (SHA:688739)

Market Cap	10.03B -14.1%
Revenue (ttm)	1.39B -17.1%
Net Income	137.62M -59.9%
EPS	0.33 -60.2%
Shares Out	411.25M
PE Ratio	73.91
Forward PE	n/a
Dividend	0.80 (3.28%)
Ex-Dividend Date	Jun 10, 2025

Volume	1,691,602
Average Volume	1,951,724
Open	23.83
Previous Close	23.99
Day's Range	23.75 - 24.45
52-Week Range	23.39 - 29.63
Beta	0.65
RSI	40.58
Earnings Date	Apr 21, 2026

About SHA:688739

Liaoning Chengda Biotechnology Co.,Ltd. a biotechnology company, engages in the research and development, production, and sales of vaccines for human use worldwide. It offers inactivated Japanese encephalitis vaccine (IJEV) and SPEEDA-rabies vaccine. The company’s rabies and influenza vaccines are in the new drug application stage; haemophilus influenzae type b vaccine in phase III; recombinant human papillomavirus 15-valent vaccine is in phase II; and 13-valent pneumococcal polysaccharide conjugate and varicella, as well as the live meningococ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 1,788
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688739

Financial Performance

In 2025, SHA:688739's revenue was 1.39 billion, a decrease of -17.06% compared to the previous year's 1.68 billion. Earnings were 137.62 million, a decrease of -59.86%.